{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T20:26:33Z","timestamp":1791491193815,"version":"4.3.4"},"reference-count":52,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Rheumatology"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.berh.2021.101725","type":"journal-article","created":{"date-parts":[[2021,12,11]],"date-time":"2021-12-11T15:34:03Z","timestamp":1639236843000},"page":"101725","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Implications of a diagnosis of rheumatoid arthritis in resource-poor countries"],"prefix":"10.1016","volume":"36","author":[{"given":"Abubakar","family":"Yerima","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Akintayo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adewale","family":"Adebajo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.berh.2021.101725_bib1","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1136\/annrheumdis-2019-215920","article-title":"Global, regional and national burden of rheumatoid arthritis 1990-2017: a systematic analysis of the Global Burden of Disease study 2017","volume":"78","author":"Safiri","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2021.101725_bib2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40744-020-00252-1","article-title":"A\u00a0review of the prevalence and unmet needs in the management of rheumatoid arthritis in Africa and the Middle East","volume":"8","author":"Almoallim","year":"2021","journal-title":"Rheumatol Ther"},{"key":"10.1016\/j.berh.2021.101725_bib3","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1007\/s10067-009-1355-0","article-title":"Rheumatoid arthritis among Nigerians: the first 200 patients from a rheumatology clinic","volume":"29","author":"Adelowo","year":"2010","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.berh.2021.101725_bib4","doi-asserted-by":"crossref","first-page":"151","DOI":"10.4236\/ojim.2017.74016","article-title":"Severity of the rheumatoid arthritis in sub-Saharan Africa: study of 403 Senegalese observations","volume":"7","author":"Niasse","year":"2017","journal-title":"Open J Intern Med"},{"key":"10.1016\/j.berh.2021.101725_bib5","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1007\/s10067-019-04431-6","article-title":"Occurrence of anti-CCP2 and RF isotypes and their relation to age and disease severity among Sudanese patients with rheumatoid arthritis","volume":"38","author":"Elshafie","year":"2019","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.berh.2021.101725_bib6","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/S1521-6942(03)00047-0","article-title":"Rheumatoid arthritis in the developing world","volume":"17","author":"Kalla","year":"2003","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"10.1016\/j.berh.2021.101725_bib7","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1007\/s10067-011-1900-5","article-title":"Response to traditional disease-modifying anti-rheumatic drugs in indigent South Africans with early rheumatoid arthritis","volume":"31","author":"Hodkinson","year":"2012","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.berh.2021.101725_bib8","first-page":"1135","article-title":"Difficult-to-treat rheumatoid arthritis: an area of unmet clinical need","volume":"57","author":"de Hair","year":"2018","journal-title":"Rheumatology"},{"key":"10.1016\/j.berh.2021.101725_bib9","doi-asserted-by":"crossref","first-page":"e000870","DOI":"10.1136\/rmdopen-2018-000870","article-title":"Window of opportunity in rheumatoid arthritis - definitions and supporting evidence: from old to new perspectives","volume":"5","author":"Burgers","year":"2019","journal-title":"RMD open"},{"key":"10.1016\/j.berh.2021.101725_bib10","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1111\/1756-185X.14001","article-title":"Delay in seeking medical help in patients with rheumatoid arthritis in India: a qualitative study","volume":"23","author":"Jain","year":"2020","journal-title":"Int J Rheumatic Dis"},{"key":"10.1016\/j.berh.2021.101725_bib11","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1093\/rheumatology\/kel215a","article-title":"British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of rheumatoid arthritis (the first two years)","volume":"45","author":"Luqmani","year":"2006","journal-title":"Rheumatology"},{"key":"10.1016\/j.berh.2021.101725_bib12","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1093\/rheumatology\/ken450a","article-title":"British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of rheumatoid arthritis (after the first 2 years)","volume":"48","author":"Luqmani","year":"2009","journal-title":"Rheumatology"},{"key":"10.1016\/j.berh.2021.101725_bib13","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1136\/annrheumdis-2019-216655","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update","volume":"79","author":"Smolen","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2021.101725_bib14","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1002\/acr.24596","article-title":"American College of rheumatology guideline for the treatment of rheumatoid arthritis","volume":"73","author":"Fraenkel","year":"2021","journal-title":"Arthritis Care Res"},{"issue":"Suppl 1","key":"10.1016\/j.berh.2021.101725_bib15","doi-asserted-by":"crossref","first-page":"S51","DOI":"10.1007\/s10067-015-3016-9","article-title":"Proper management of rheumatoid arthritis in Latin America. What the guidelines say?","volume":"34","author":"Brenol","year":"2015","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.berh.2021.101725_bib16","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1186\/1471-2474-15-333","article-title":"Patient participation in decisions about disease modifying anti-rheumatic drugs: a cross-sectional survey","volume":"15","author":"Nota","year":"2014","journal-title":"BMC Muscoskel Disord"},{"key":"10.1016\/j.berh.2021.101725_bib17","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1748-5908-1-16","article-title":"Barriers and facilitators to implementing shared decision-making in clinical practice: a systematic review of health professionals' perceptions","volume":"1","author":"Gravel","year":"2006","journal-title":"Implement Sci"},{"key":"10.1016\/j.berh.2021.101725_bib18","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S0140-6736(04)16676-2","article-title":"Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial","volume":"364","author":"Grigor","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.berh.2021.101725_bib19","first-page":"102","article-title":"Pharmacogenetics of methotrexate in rheumatoid arthritis: a systematic review","volume":"23","author":"Restrepo","year":"2016","journal-title":"Rev Colomb Reumatol"},{"key":"10.1016\/j.berh.2021.101725_bib20","first-page":"572","article-title":"Methotrexate (MTX) pathway gene polymorphisms and their effects on MTX toxicity in Caucasian and African American patients with rheumatoid arthritis","volume":"35","author":"Ranganathan","year":"2008","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.berh.2021.101725_bib21","first-page":"218","article-title":"Tolerance and observance of methotrexate in the treatment of rheumatoid arthritis at the university Hospital Bogodogo, Burkina Faso","volume":"13","author":"Zongo","year":"2019","journal-title":"African Journal of Pharmacy and Pharmacology"},{"key":"10.1016\/j.berh.2021.101725_bib22","first-page":"49","article-title":"Overweight and obesity affect clinical assessment of synovitis in rheumatoid arthritis: comparison of ultrasonography and clinical exam","volume":"37","author":"Goossens","year":"2019","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.berh.2021.101725_bib23","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1002\/acr.21768","article-title":"Obesity and reduction of the response rate to anti\u2013tumor necrosis factor \u03b1 in rheumatoid arthritis: an approach to a personalized medicine","volume":"65","author":"Gremese","year":"2013","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.berh.2021.101725_bib24","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1038\/nrrheum.2013.134","article-title":"Biologic agents in rheumatology: unmet issues after 200 trials and $200 billion sales","volume":"9","author":"Ioannidis","year":"2013","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.berh.2021.101725_bib25","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1007\/s10067-014-2841-6","article-title":"The global challenges and opportunities in the practice of rheumatology: white paper by the World Forum on Rheumatic and Musculoskeletal Diseases","volume":"34","author":"Al Maini","year":"2015","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.berh.2021.101725_bib26","series-title":"Biologic therapy for rheumatoid arthritis in developing countries\u2014a place for non-TNF inhibitors as first-line treatment","author":"Tikly","year":"2015"},{"key":"10.1016\/j.berh.2021.101725_bib27","first-page":"2021","article-title":"Prevalence of latent tuberculosis infection in the Middle East and North Africa: a systematic review","author":"Barry","year":"2021","journal-title":"Pulmonary Medicine"},{"key":"10.1016\/j.berh.2021.101725_bib28","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0224963","article-title":"A\u00a0population-based study of tuberculosis incidence among rheumatic disease patients under anti-TNF treatment","volume":"14","author":"Sartori","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.berh.2021.101725_bib29","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1002\/art.20009","article-title":"Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy","volume":"50","author":"Wolfe","year":"2004","journal-title":"Arthritis Rheum: Official Journal of the American College of Rheumatology"},{"key":"10.1016\/j.berh.2021.101725_bib30","doi-asserted-by":"crossref","first-page":"s477","DOI":"10.1016\/j.rbr.2017.05.003","article-title":"Incidence of tuberculosis among patients with rheumatoid arthritis using TNF blockers in Brazil: data from the Brazilian registry of biological Therapies in rheumatic diseases (registro brasileiro de Monitora\u00e7\u00e3o de Terapias biol\u00f3gicas-BiobadaBrasil)","volume":"57","author":"Yonekura","year":"2017","journal-title":"Rev Bras Reumatol"},{"key":"10.1016\/j.berh.2021.101725_bib31","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1136\/ard.2009.118935","article-title":"Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR)","volume":"69","author":"Dixon","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2021.101725_bib32","series-title":"Latent tuberculosis infection: updated and consolidated guidelines for programmatic management","author":"Global Tuberculosis Programme","year":"2018"},{"key":"10.1016\/j.berh.2021.101725_bib33","doi-asserted-by":"crossref","first-page":"11941","DOI":"10.3748\/wjg.v21.i42.11941","article-title":"Hepatitis B virus burden in developing countries","volume":"21","author":"Zampino","year":"2015","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.berh.2021.101725_bib34","series-title":"Who guidelines for the prevention, care and treatment of persons with chronic hepatitis B virus infection","author":"World Health Organization","year":"2015"},{"key":"10.1016\/j.berh.2021.101725_bib35","series-title":"Chronic hepatitis B infection in sub-Saharan Africa: a grave challenge and a great hope","author":"Stockdale","year":"2015"},{"key":"10.1016\/j.berh.2021.101725_bib36","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1111\/j.1600-6143.2010.03401.x","article-title":"Early prediction of cardiac allograft vasculopathy and heart transplant failure","volume":"11","author":"Labarrere","year":"2011","journal-title":"Am J Transplant"},{"key":"10.1016\/j.berh.2021.101725_bib37","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1007\/s10067-019-04448-x","article-title":"Chronic hepatitis B viral infection among RA patients\u2014a cross-sectional control study","volume":"38","author":"Mahroum","year":"2019","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.berh.2021.101725_bib38","article-title":"Reactivation of hepatitis B virus infection in rheumatic diseases: risk and management considerations","volume":"12","author":"Koutsianas","year":"2020","journal-title":"Therapeutic Adv Musculoskeletal Dis"},{"key":"10.1016\/j.berh.2021.101725_bib39","first-page":"2564","article-title":"Treatment or prophylaxis against hepatitis B virus infection in patients with rheumatic disease undergoing immunosuppressive therapy: an update","volume":"10","author":"Stasi","year":"2021","journal-title":"J\u00a0Clin Med"},{"key":"10.1016\/j.berh.2021.101725_bib40","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1007\/s12072-014-9597-6","article-title":"Long-term use of methotrexate does not result in hepatitis B reactivation in rheumatologic patients","volume":"9","author":"Laohapand","year":"2015","journal-title":"Hepatology international"},{"key":"10.1016\/j.berh.2021.101725_bib41","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1136\/annrheumdis-2016-209973","article-title":"Incidence of hepatitis B virus reactivation in patients with resolved infection on immunosuppressive therapy for rheumatic disease: a multicentre, prospective, observational study in Japan","volume":"76","author":"Fukuda","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2021.101725_bib42","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1053\/j.gastro.2014.10.038","article-title":"American Gastroenterological Association Institute technical review on prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy","volume":"148","author":"Perrillo","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.berh.2021.101725_bib43","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1136\/annrheumdis-2017-211322","article-title":"Reactivation of hepatitis B virus infection in patients with rheumatoid arthritis receiving tofacitinib: a real-world study","volume":"77","author":"Chen","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2021.101725_bib44","series-title":"FRI0077 Hepatitis b virus reactivation in patients with rheumatoid arthritis treated with baricitinib: post-hoc analysis from clinical trials","author":"Harigai","year":"2018"},{"key":"10.1016\/j.berh.2021.101725_bib45","series-title":"The global HIV\/AIDS epidemic","year":"2021"},{"key":"10.1016\/j.berh.2021.101725_bib46","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1002\/art.1780381124","article-title":"A\u00a0reexamination of the relationship between active rheumatoid arthritis and the acquired immunodeficiency syndrome","volume":"38","author":"Ornstein","year":"1995","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2021.101725_bib47","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1007\/s00296-017-3690-9","article-title":"Use of etanercept to treat rheumatoid arthritis in an HIV-positive patient: a case-based review","volume":"37","author":"Liang","year":"2017","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.berh.2021.101725_bib48","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.3899\/jrheum.130896","article-title":"Effect of human immunodeficiency virus infection on disease activity in rheumatoid arthritis: a retrospective study in South Africans","volume":"41","author":"Tarr","year":"2014","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.berh.2021.101725_bib49","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.jmii.2013.08.002","article-title":"Autoimmune diseases-related arthritis in HIV-infected patients in the era of highly active antiretroviral therapy","volume":"48","author":"Yang","year":"2015","journal-title":"J\u00a0Microbiol Immunol Infect"},{"key":"10.1016\/j.berh.2021.101725_bib50","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.autrev.2015.01.001","article-title":"HIV\/AIDS and rheumatoid arthritis","volume":"14","author":"Cunha","year":"2015","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.berh.2021.101725_bib51","first-page":"51","article-title":"Rheumatoid arthritis in patients with HIV: management challenges","volume":"8","author":"Carroll","year":"2016","journal-title":"Open Access Rheumatol Res Rev"},{"key":"10.1016\/j.berh.2021.101725_bib52","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12879-016-1389-2","article-title":"Inflammatory arthritis in HIV positive patients: a practical guide","volume":"16","author":"Adizie","year":"2016","journal-title":"BMC Infect Dis"}],"container-title":["Best Practice & Research Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152169422100067X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152169422100067X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T17:22:41Z","timestamp":1761499361000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S152169422100067X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":52,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["S152169422100067X"],"URL":"https:\/\/doi.org\/10.1016\/j.berh.2021.101725","relation":{},"ISSN":["1521-6942"],"issn-type":[{"value":"1521-6942","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Implications of a diagnosis of rheumatoid arthritis in resource-poor countries","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Rheumatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.berh.2021.101725","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"101725"}}